Carregant...
Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
Human EGF Receptor 2 (HER2) is an important oncogene driving aggressive metastatic growth in up to 20% of breast cancer tumors. At the same time, it presents a target for passive immunotherapy such as trastuzumab (TZM). Although TZM has been widely used clinically since 1998, not all eligible patien...
Guardat en:
| Publicat a: | Molecules |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7767145/ https://ncbi.nlm.nih.gov/pubmed/33348564 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/molecules25245976 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|